ArticleJournal of substance abuse treatment2013
Initiation of buprenorphine during incarceration and retention in treatment upon release.
Article in Journal of substance abuse treatment, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 4 syntheses or guidelines pooled it, 93 citations in OpenAlex.
- Interventions to reduce harms related to drug use among people who experience incarceration: systematic review and meta-analysis.The Lancet. Public health · 2024Pooled it
- Factors Associated with Long-Term Retention in Buprenorphine-Based Addiction Treatment Programs: a Systematic Review.Journal of general internal medicine · 2022Pooled it
- Routes of non-traditional entry into buprenorphine treatment programs.Substance abuse treatment, prevention, and policy · 2020Pooled it
- Opioid-related treatment, interventions, and outcomes among incarcerated persons: A systematic review.PLoS medicine · 2019Pooled it
- A randomized, open label trial of methadone continuation versus forced withdrawal in a combined US prison and jail: Findings at 12 months post-release.Drug and alcohol dependence · 2018Trial
- A randomized clinical trial of buprenorphine for prisoners: Findings at 12-months post-release.Drug and alcohol dependence · 2017Trial
- Extended-release naltrexone for pre-release prisoners: A randomized trial of medical mobile treatment.Contemporary clinical trials · 2017Trial
- Buprenorphine dose induction in non-opioid-tolerant pre-release prisoners.Drug and alcohol dependence · 2015Trial
- A randomized controlled trial of prison-initiated buprenorphine: prison outcomes and community treatment entry.Drug and alcohol dependence · 2014Trial
- Statewide implementation of MOUD in jails: aligning barriers and strategies in the quest for acceptability and feasibility.Health & justice · 2026Article
- Medication for opioid use disorder service delivery in carceral facilities: update and summary report.Health & justice · 2025Review
- The association between attitudes and the provision of medications for opioid use disorder (MOUD) in United States jails.Drug and alcohol dependence reports · 2024Article
- The relationship between reincarceration and treatment of opioid use disorder with extended-release naltrexone among persons with HIV.Drug and alcohol dependence reports · 2023Article
- Medications for opioid use disorder during incarceration and post-release outcomes.Health & justice · 2023Article
- Incarceration status at buprenorphine initiation and OUD treatment outcomes during pregnancy.Frontiers in psychiatry · 2023Article
- Buprenorphine/naloxone access for people with opioid use disorder in correctional facilities: taking steps to support knowledge translation.Health & justice · 2022Article
- Medications for opioid use disorder during pregnancy: Access and continuity in a state women's prison facility, 2016-2019.Drug and alcohol dependence · 2022Article
- Opioid-specific medication-assisted therapy and its impact on criminal justice and overdose outcomes.Campbell systematic reviews · 2022Article
- Factors associated with opioid-involved overdose among previously incarcerated people in the U.S.: A community engaged narrative review.The International journal on drug policy · 2022Review
- Feasibility and Acceptability of a Digital Health Intervention to Promote Continued Engagement in Medication for Opioid Use Disorder Following Release From Jail/Prison.Substance abuse : research and treatment · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
We report here on a feasibility study of initiating buprenorphine/naloxone prior to release from incarceration and linking participants to community treatment providers upon release. The study consisted of a small number of Rhode Island (RI) prisoners (N = 44) diagnosed with opioid dependence. The study design is a single arm, open-label pilot study with a 6-month follow up interview conducted in the community. However, a natural experiment arose during the study comparing pre-release initiation of buprenorphone/naloxone to initiation post-release. Time to post-release prescriber appointment (mean days) for initiation of treatment outside Rhode Island Department of Corrections (RIDOC) versus inside RIDOC was 8.8 and 3.9, respectively (p = .1). Median post release treatment duration (weeks) for outside RIDOC versus inside RIDOC was 9 and 24, respectively (p = .007). We conclude that initiating buprenorphine/naloxone prior to release from incarceration may increase engagement and retention in community-based treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.